RTX vs SCNI · P/E 36, rev $46.78B vs P/E 0.2, rev $1.3M
RTX Corporation (RTX) versus Scinai Immunotherapeutics Ltd (SCNI) — a side-by-side from cached financials, not a winner call.
RTX Corporation (RTX) is a aerospace & defense company listed on NYSE. It is led by Chris Calio.
Scinai Immunotherapeutics Ltd (SCNI) is a biotechnology company listed on NASDAQ.
Latest reported RTX revenue for 2026-06-30 was $46.78B. Net income was $4.20B. RTX currently screens at market cap $259.34B and trailing P/E 36.2.
Latest reported SCNI revenue for 2025-12-31 was $1.3M. Net income was -$8.3M. Revenue was up 99.2% from 2024-12-31 to 2025-12-31. SCNI currently screens at market cap $1.8M and trailing P/E 0.2.
RTX currently screens at market cap $259.34B and trailing P/E 36.2. SCNI currently screens at market cap $1.8M and trailing P/E 0.2.
Not investment advice. Open the RTX and SCNI stock pages for the full models.
Not investment advice.